Continue sertraline | Combine with mirtazapine | Switch to mirtazapine | Combine vs continue | Switch vs continue | Combine vs switch | |
---|---|---|---|---|---|---|
Least squares mean (95% CI) | Least squares mean (95% CI) | Least squares mean (95% CI) | Adjusteda difference (95% CI) P value | Adjusteda difference (95% CI) P value | Adjusteda difference (95% CI) P value | |
PHQ-9 | 6.58 (6.09 to 7.07) | 6.37 (5.88 to 6.87) | 6.61 (6.12 to 7.10) | −0.20 (− 0.80 to 0.40) P = 0.51 | 0.03 (− 0.56 to 0.63) P = 0.91 | −0.24 (− 0.84 to 0.37) P = 0.44 |
BDI-II | 14.09 (13.15 to 15.03) | 13.45 (12.49 to 14.41) | 13.72 (12.78 to 14.67) | −0.64 (− 1.88 to 0.60) P = 0.31 | −0.37 (− 1.59 to 0.86) P = 0.56 | −0.27 (− 1.51 to 0.96) P = 0.66 |
FIBSER | 4.34 (4.10 to 4.59) | 4.46 (4.21 to 4.71) | 4.48 (4.24 to 4.72) | 0.12 (−0.23 to 0.47) P = 0.51 | 0.14 (−0.21 to 0.48) P = 0.44 | − 0.02 (− 0.36 to 0.33) P = 0.92 |
Raw numbers (%) | Raw numbers (%) | Raw numbers (%) | Adjustedb OR (95% CI) P value | Adjustedb OR (95% CI) P value | Adjustedb OR (95% CI) P value | |
Proportion of remission | 245/538 (45.5%) | 263/520 (50.3%) | 262/540 (48.5%) | 1.24 (0.96 to 1.49) P = 0.10 | 1.16 (0.90 to 1.48), P = 0.25 | 1.07 (0.80 to 1.37) P = 0.60 |
Mean (SE) | Mean (SE) | Mean (SE) | HR (95% CI) P value | HR (95% CI) P value | HR (95% CI) P value | |
Time to discontinuation of allocated treatment by week 25 | 15.97 (0.30) | 15.23 (0.32) | 15.56 (0.31) | 1.07 (0.92 to 1.25) P = 0.40 | 1.04 (0.89 to 1.21) P = 0.64 | 1.03 (0.88 to 1.20) P = 0.70 |
Time to discontinuation of any treatment by week 25 | 17.32 (0.17) | 20.47 (0.23) | 20.22 (0.23) | 0.89 (0.69 to 1.14) P = 0.35 | 1.08 (0.85 to 1.38) P = 0.51 | 0.82 (0.64 to 1.05) P = 0.11 |
Mean (SD) | Mean (SD) | Mean (SD) | ||||
Sertraline prescribed at week 52 (mg/day) | 51.6 (38.5), n = 448 | 51.2 (38.3), n = 440 | 10.3 (24.7), n = 457 | |||
Mirtazapine prescribed at week 52 (mg/day) | 3.9 (10.6), n = 448 | 12.3 (13.0), n = 440 | 14.6 (13.8), n = 456 |